Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2395840 (Fulmetibant) in Diabetic Neuropathic Pain
NCT05219812Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of fulmetibant in diabetic neuropathy, sponsored by Bayer. Started Feb 2022; status: completed.
02
Drugs
fulmetibant
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT05219812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219812.